Aridis Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-…

Biotechnology
US, Los Gatos [HQ]
Financials

Analysts

Reported
Past Estimate Consensus
Future Estimate Consensus
Aridis Pharmaceuticals, Inc. can't present any analysts estimates at the moment detail analysis.
End of ARDS's Analysis
CIK: 1614067 CUSIP: 040334104 ISIN: US0403341045 LEI: - UEI: -
Secondary Listings
ARDS has no secondary listings inside our databases.